DNA/RNA markers for colorectal cancer risk in preserved stool specimens: A pilot study

Tumori

Volumn 95, Issue 6, 2009, Pages 753-761

  Kato, Ikuko ^a,b   Badsha, Kawsar Z ^a   Land, Susan ^a,b   Nechvatal, Jordan M ^b   Matherly, Larry H ^a,b   Tarca, Adi L ^a,c   Majumdar, Adhip P ^a,b   Basson, Marc D ^a,b,d   Ram, Jeffrey L ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Wayne State University   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Colorectal cancer; DNA; RNA; Stool test

Indexed keywords

BISULFITE; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; MOLECULAR MARKER;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER RISK; CIGARETTE SMOKING; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FAMILY HISTORY; FECES ANALYSIS; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; POLYP; PROMOTER REGION; PROTEIN EXPRESSION; QUESTIONNAIRE;

EID: 76349120403     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160909500619     Document Type: Article

References (52)

1. Iyengar V, Albaugh GP, Lohani A, Nair PP: Human stools as a source of viable colonic epithelial cells. FASEB J, 5: 2856-2859, 1991.
2. Desilets DJ, Davis KE, Nair PP, Salata KF, Maydonovitch CL, Howard RS, Kikendall JW, Wong RK: Lectin binding to human colonocytes is predictive of colonic neoplasia. Am J Gastroenterol, 94: 744-750, 1999.
3. Osborn NK, Ahlquist DA: Stool screening for colorectal cancer: Molecular approaches. Gastroenterology, 128: 192-206, 2005.
4. Davis CD: Use of exfoliated cell from target tissues to pre-diet responses to bioactive food components. J Nutr, 133: 1769-1772, 2003.
5. Yu Y, Majumdar APN, Nechvatal JM, Ram JL, Basson MD, Heilbrun LK, Kato I: Exfoliated cells in stool: A source for RT-PCR based analysis of biomarkers of gastrointestinal cancer. Cancer Epidemiol Biomarkers Prev, 17: 455-458, 2008.
6. Nechvatal JM, Ram JL, Basson MD, Namprachan P, Niec SR, Badsha KZ, Matherly LH, Majumdar AN, Kato I: Fecal collection, ambient preservation, and DNA extraction for PCR amplification of bacterial and human markers from human feces. J Microbiol Methods, 72: 124-132, 2008.
7. Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC 3rd, Sontag S, Johnson D, Skoletsky J, Durkee K, Markowitz S, Shuber A: Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol, 5: 111-117, 2007.
8. Leung WK, To KF, Man EP, Chan MW, Hui AJ, Ng SS, Lau JY, Sung JJ: Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol, 102: 1070-1076, 2007.
9. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB: Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet, 7: 536-540, 1994.
10. Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M: Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology, 127: 422-427, 2004.
11. Vallböhmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen S, Lenz HJ: Molecular determinants of cetuximab efficacy. J Clin Oncol, 23: 3536-3544, 2005.
12. Van Engeland M, Weijenberg MP, Roemen GMJM, Brink M, de Bruine AP, Goldbohm RA, van den Brandt PA, Baylin SB, de Goeij AFPM, Herman JG: Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands Cohort Study on Diet and Cancer. Cancer Res, 63: 3133-3137, 2003.
13. Zochbauer-Muller S, Lam S, Toyooka S, Virmani AK, Toyooka KO, Seidl S, Minna JD, Gazdar AF: Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer, 107: 612-616, 2003.
14. Wong TS, Man MWL, Lam AKY, Wei WI, Kwong YL, Yuen APW: The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR. Eur J Cancer, 39: 1881-1887, 2003.
15. Pereira MA, Tao L, Wang W, Li Y, Umar A, Steele VE, Lubet RA: Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors. Carcinogenesis, 25: 1917-1923, 2004.
16. Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, Fukuyama Y, Virmani AK, Zochbauer-Muller S, Tsukuda K, Sugio K, Shimizu N, Shimizu K, Lee H, Chen CY, Fong KM, Gilcrease M, Roth JA, Minna JD, Gazdar AF: Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer, 103: 153-160, 2003.
17. WCRF/AICR: 4.8 Alcoholic drinks. In: Food, nutrition, physical activity and the prevention of cancer: a global perspective, pp 157-171, AICR, Washington DC, 2007.
18. Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P: Smoking and colorectal cancer: a meta-analysis. JAMA, 300: 2765-2778, 2008.
19. Botteri E, Iodice S, Raimondi S, Maisonneuve P, Lowenfels AB. Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology, 134: 388-395, 2008.
20. IARC: IARC handbooks of cancer prevention, Vol 1. Nonsteroidal anti-inflammatory drugs. IARC, Lyon, 1997.
21. Olson J, Whitney DH, Durkee K, Shuber AP: DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests. Diagn Mol Pathol, 14: 183-191, 2005.
22. Zou H, Harrington JJ, Matt KK, Ahlquist DA: A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev, 15: 1115-1119, 2006.
23. Itzkowitz S, Brand R, Jandorf L, Durkee K, Millholland J, Rabeneck L, Schroy PC 3rd, Sontag S, Johnson D, Markowitz S, Paszat L, Berger BM: A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol, 103: 2862-2770, 2008.
24. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA: Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res, 61: 3573-3577, 2001.
25. Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Grieu F, Watanabe G, Iacopetta B: DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer, 94: 593-598, 2006.
26. Khazaie K, Schirrmacher V, Lichtner RB: EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev, 12: 255-274, 1993.
27. Malecka-Panas E, Kordek R, Biernat W, Tureaud J, Liberski PP, Majumdar APN: Differential activation of total and EGF receptor tyrosine kinase in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. Hepatogastroenterology, 44: 435-440, 1997.
28. Brandt B, Hermann S, Straif K, Tidow N, Buerger H, Chang-Claude J: Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene. Cancer Res, 64: 7-12, 2004.
29. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N, Zakowski M, Rusch V, Heelan RT: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol, 22: 1103-1109, 2004.
30. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med, 353: 1331-1344, 2005.
31. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bernis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregore V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst, 97: 643-655, 2005.
32. Zhang XT, Li LY, Mu XL, Cui QC, Chang XY, Song W, Wang SL, Wang MZ, Zhong W, Zhang L: The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol, 16: 1334-1342, 2005.
33. Clark GM, Zborowski DM, Santabarbara P, Ding K, Whitehead M, Seymour L, Shepherd FA; National Cancer Institute of Canada Clinical Trials Group: Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer, 7: 389-394, 2006.
34. Zheng Z, Bepler G, Cantor A, Haura EB: Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer. Chest, 128: 308-316, 2005.
35. Sugio K, Uramoto H, Ono K, Oyama T, Hanagiri T, Sugaya M, Ichiki Y, So T, Nakata S, Morita M, Yasumoto K: Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer, 94: 896-903, 2006.
36. Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH, Park JY: EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet, 173: 107-113, 2007.
37. Mounawar M, Mukeria A, Le Calvez F, Hung RJ, Renard H, Cortot A, Bollart C, Zaridze D, Brennan P, Boffetta P, Brambilla E, Hainaut P: Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res, 67: 5667-5672, 2007.
38. Na II, Rho JK, Choi YJ, Kim CH, Park JH, Koh JS, Ryoo BY, Yang SH, Lee JC: The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression. Lung Cancer, 57: 96-102, 2007.
39. Sasaki H, Kawano O, Endo K, Yukiue H, Yano M, Fujii Y: EGFRvIII mutation in lung cancer correlates with increased EGFR copy number. Oncol Rep, 17: 319-323, 2007.
40. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A, 101: 13306-13311, 2004.
41. Jeon YK, Sung SW, Chung JH, Park WS, Seo JW, Kim CW, Chung DH: Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer, 54: 387-398, 2006.
42. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol, 6: 279-286, 2005.
43. Seitz HK, Simanowski UA: Cell turnover in the gastrointestinal tract and the effect of ethanol. In: Alcohol and the gastrointestinal tract, Preedy VR, Watson RR (Eds), pp 273-287, CRC Press, Boca Rato, FL, 1996.
44. Simanowski UA, Homann N, Knühl M, Arce L, Waldherr R, Conradt C, Bosch FX, Seitz HK: Increased rectal cell proliferation following alcohol abuse. Gut, 49: 418-422, 2001.
45. Vincon P, Wunderer J, Simanowski UA, Koll M, Preedy VR, Peters TJ, Werner J, Waldherr R, Seitz HK: Inhibition of alcohol-associated colonic hyperregeneration by alpha-tocopherol in the rat. Alcohol Clin Exp Res, 27: 100-106, 2003.
46. Amin PB, Diebel LN, Liberati DM: The intestinal epithelial cell modulates the effect of alcohol on neutrophil inflammatory potential. J Trauma, 63: 1223-1229, 2007.
47. Fleming S, Toratani S, Shea-Donohue T, Kashiwabara Y, Vogel SN, Metcalf ES: Pro- and anti-inflammatory gene expression in the murine small intestine and liver after chronic exposure to alcohol. Alcohol Clin Exp Res, 25: 579-589, 2001.
48. Shames DS, Minna JD, Gazdar AF: Methods for detecting DNA methylation in tumors: from bench to bedside. Cancer Lett, 251: 187-198, 2007.
49. Ho SM, Tang WY: Techniques used in studies of epigenome dysregulation due to aberrant DNA methylation: an emphasis on fetal-based adult diseases. Reprod Toxicol, 23: 267-282, 2007.
50. Coudry RA, Meireles SI, Stoyanova R, Cooper HS, Carpino A, Wang X, Engstrom PF, Clapper ML: Successful application of microarray technology to microdissected formalin-fixed, paraffin-embedded tissue. J Mol Diagn, 9: 70-79, 2007.
51. Soegaard M, Jensen A, Frederiksen K, Høgdall E, Høgdall C, Blaakaer J, Kjaer SK: Accuracy of self-reported family history of cancer in a large case-control study of ovarian cancer. Cancer Causes Control, 19: 469-479, 2008.
52. Sung JJ, Lau JY, Young GP, Sano Y, Chiu HM, Byeon JS, Yeoh KG, Goh KL, Sollano J, Rerknimitr R, Matsuda T, Wu KC, Ng S, Leung SY, Makharia G, Chong VH, Ho KY, Brooks D, Lieberman DA, Chan FK; Asia Pacific Working Group on Colorectal Cancer: Asia Pacific consensus recommendations for colorectal cancer screening. Gut, 57: 1166-1176, 2008.